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Abstract
Background: Esophageal adenocarcinoma (EAC) incidence is increasing rapidly. Esophageal cancer has the second
lowest 5-year survival rate of people diagnosed with cancer in Canada. Given the poor survival and the potential for
further increases in incidence, phase-specific cost estimates constitute an important input for economic evaluation
of prevention, screening, and treatment interventions. The study aims to estimate phase-specific net direct medical
costs of care attributable to EAC, costs stratified by cancer stage and treatment, and predictors of total net costs of
care for EAC.
Methods: A population-based retrospective cohort study was conducted using Ontario Cancer Registry-linked
administrative health data from 2003 to 2011. The mean net costs of EAC care per 30 patient-days (2016 CAD)
were estimated from the payer perspective using phase of care approach and generalized estimating equations.
Predictors of net cost by phase of care were based on a generalized estimating equations model with a logarithmic
link and gamma distribution adjusting for sociodemographic and clinical factors.
Results: The mean net costs of EAC care per 30 patient-days were $1016 (95% CI, $955–$1078) in the initial phase,
$669 (95% CI, $594–$743) in the continuing care phase, and $8678 (95% CI, $8217–$9139) in the terminal phase.
Overall, stage IV at diagnosis and surgery plus radiotherapy for EAC incurred the highest cost, particularly in the
terminal phase. Strong predictors of higher net costs were receipt of chemotherapy plus radiotherapy, surgery
plus chemotherapy, radiotherapy alone, surgery alone, and chemotherapy alone in the initial and continuing care
phases, stage III-IV disease and patients diagnosed with EAC later in a calendar year (2007–2011) in the initial and
terminal phases, comorbidity in the continuing care phase, and older age at diagnosis (70–74 years), and geographic
region in the terminal phase.
Conclusions: Costs of care vary by phase of care, stage at diagnosis, and type of treatment for EAC. These cost
estimates provide information to guide future resource allocation decisions, and clinical and policy interventions
to reduce the burden of EAC.
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Background
Esophageal cancer is the eighth most common cancer
worldwide [1]. The incidence of esophageal adenocarcin-
oma (EAC) has increased rapidly in North America and
other Western countries over the past several decades
[2–6]. In fact, EAC has become the predominant histo-
logical subtype of esophageal cancer (relative to squa-
mous cell carcinoma) in North America and Europe,
and the sixth leading cause of cancer-related deaths
worldwide [1, 7, 8]. In Canada, the incidence of EAC
has risen steadily at 4% per year over the past 30 years
(between 1981 and 2009), making it the most com-
mon type of esophageal cancer in Ontario [9]. These
trends may be attributed to a growing and aging
population, and the rise in the prevalence of import-
ant risk factors, such as obesity and gastroesophageal
reflux disease (GERD) which leads to the develop-
ment of Barrett’s esophagus [7, 9–11]. Esophageal
cancers symptomatically present late and carry poor
prognoses, despite advances in multimodality treat-
ment [12, 13]. Esophageal cancer has the second low-
est 5-year relative survival rate for people diagnosed
with cancer in Canada (i.e., pancreatic cancer 9.5%,
esophageal cancer 15.3%, lung cancer 20%, and liver
cancer 20.4%) [14]. Therefore, diagnosing esophageal
cancers at an early stage before the development of
symptoms, is critical for improving prognosis [15].
Recent cancer-related cost estimates placed esophageal
cancer patients who survived for more than 1 year
post-diagnosis at the top of the cost table at $50,620
(95% CI $47,677–$53,562, 2009 Canadian dollars) [16].
These patients also had the highest cost for hospital ad-
missions of all cancers ($27,506) due to the performance
of resource intensive procedures, such as post-surgery
esophageal dilation and biopsies to the esophagus or
other parts of the gastrointestinal tract (through endos-
copies) [16]. Additionally, these patients had frequent
post-treatment follow-up visits [17], demonstrated by
high costs for physician services ($4757) and home care
($4058) [16]. The costs were higher in the initial and
terminal phases, and lower in the pre-diagnosis and con-
tinuing phases [18]. However, these studies provide esti-
mates for EAC care that are broad in categorization, and
more detailed estimates by specific clinical care elements
and characteristic could provide significant data to guide
clinical care, policy and future research.
Techniques to reduce EAC incidence, such as endo-
scopic mucosal resection or radiofrequency ablation of
Barrett’s esophagus, will likely be more cost-effective
than current surveillance strategies that rely on early de-
tection of cancer [19, 20]. There is, however, limited
relevant evidence in the Canadian context; costs esti-
mates of EAC are needed for use in cost-effectiveness
analyses of innovative technologies to inform health care
professionals, policy makers, and the public in order to
aid prevention and the early detection of EAC.
The purpose of this study was to estimate: i) the
phase-specific net direct medical costs of care attribut-
able to EAC for all adults aged 18 years and older, from
the perspective of the Ontario Ministry of Health and
Long-Term Care; ii) total net health care costs by cancer
stage and type of treatment for EAC; and iii) predictors
of the total net costs of care for individuals diagnosed
with EAC.
Methods
Study design and setting
We conducted a population-based retrospective cohort
study by linking the Ontario Cancer Registry (OCR) with
administrative health data and a reference Ontario popu-
lation to estimate the phase-specific net costs of care for
primary EAC from January 1, 2003, through December
31, 2011. Individuals were followed from the day of diag-
nosis until death or until 12 months after the end of the
study period, i.e., December 31, 2012, whichever came
first. We approached costing [21–25] based on three
care phases: 1) initial phase, the first 12 months after
diagnosis of EAC, which would include diagnostic ser-
vices, primary therapy, and adjuvant therapy to lower
the risk of cancer recurrence; 2) continuing care phase,
all months between the initial and terminal phases of
care, which would include surveillance activities for
detecting recurrences, follow-up treatment to prevent
cancer recurrence, and treatment of complications
following the initial therapy; and 3) the terminal phase,
the final 12 months before death, which applies to care
received at the end of life, often palliative in nature. For
patients who died within 12 months post-diagnosis, the
costs were attributed to the terminal phase only. For pa-
tients surviving < 24 months after diagnosis, the final
12 months of observation and costs of care were allo-
cated to the terminal phase first while the remaining
months were allocated to the initial phase [21, 25]. For
patients who did not die during the study period, the
first 12 months (and costs) were allocated to the initial
phase and all remaining months were allocated to con-
tinuing care phase [22]. We estimated phase-specific net
costs of care as the difference between the mean costs
for EAC cases and for matched controls without cancer
[22, 24, 25]. Additionally, we stratified total net costs by
stage at diagnosis and treatment for EAC, and identified
predictors of total net costs.
Data sources
We conducted our analyses using population-level
administrative health databases with information on all
14 million Ontario residents. Data were provided by the
Institute for Clinical Evaluative Sciences, the main data
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repository for health records in the province of Ontario,
Canada. These data have been validated for completeness
and accuracy [26–31]. This included cancer registry linked
to demographic and geographic information, physician
billings for outpatient, inpatient, community-based, and
laboratory services, hospital and emergency department
discharge abstracts, hospital-based ambulatory care data,
and prescription drugs (for those over age 65), home care,
continuing care, and long-term care [32, 33].
All cancer incidence in Ontario and subsequent mor-
tality has been captured by the OCR from 1964 onwards.
The Registered Persons Database contains demographic
and geographic information for all people registered for
provincial government-sponsored health insurance
coverage. The Ontario Health Insurance Plan (OHIP)
claims database contains the records of all physician bil-
lings for outpatient, inpatient, community-based, and la-
boratory services starting from July 1991. Non-physician
procedures with an OHIP billing number (for example,
midwife, chiropractor, nurse practitioner, or physiother-
apist) are also included. Billings are based on the On-
tario Health Insurance Plan fee-for-service rates in effect
in the year the services were provided. The Canadian
Institute for Health Information Discharge Abstract
Database (CIHI-DAD) contains demographic, clinical,
and administrative information on inpatient hospitaliza-
tions from April 1988 onwards; and CIHI-National
Ambulatory Care Reporting System (CIHI-NACRS) con-
tains administrative, demographic, clinical, and financial
data for hospital-based and community-based ambula-
tory care (day surgery, emergency department visits, out-
patient and community-based clinics) which is available
from April 2003 onwards. OHIP, CIHI-DAD, and
CIHI-NACRS fee codes were used to identify surgical re-
section, chemotherapy and radiotherapy, as well as esopha-
geal dilation, drainage, esophageal stenting, laser debulking
of tumor, and palliative care for EAC (see Additional file 1:
Table S1). We used previously published and validated fee
codes for these procedures [34].
Direct medical costs were determined using the per-
spective of the public payer. The costing methods
followed the guidelines of the Canadian Agency for
Drugs and Technology in Health [33] and the Health
System Performance Research Network [32], and were
based on previous cancer costing work done in Ontario
[16, 18, 35]. Costs associated with physician services, in-
cluding outpatient visits, laboratory services, diagnostic
tests, emergency physicians, and medical and radiation
oncologists, were determined through the OHIP claims
database. The cost of inpatient hospitalization was deter-
mined from the CIHI-DAD database. Costs associated
surgical resection, chemotherapy and radiotherapy for
EAC were determined using the CIHI and OHIP data-
bases with application of standard provincial unit costs.
Emergency department visit and same-day surgery costs
came from the CIHI-NACRS database. Ontario Drug
Benefit Program database contains the cost of prescrip-
tion medication dispensed to individuals 65 years of age
and older, resident of a long-term care facility or a home
for special care, recipient of services under the Home
Care Program, recipient of social assistance (Ontario
Works, Ontario Disability Support Program), registered
under the Trillium Drug Program, or registered under
the Special Drugs Program. The Ontario Home Care
Services, Continuing Care Reporting System, and OHIP/
Ontario Drug Benefit Program databases were used to
identify costs associated with home care, continuing care
(chronic care), and long-term care.
Study variables
Variables considered in the analyses included sociode-
mographic characteristics: age group at diagnosis (< 50,
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, ≥
85 years); gender (male, female); residence (rural, urban);
birth country (outside of Canada, Canada); area-level in-
come quintile (Q1-lowest; Q5-highest); Ontario adminis-
trative health region (Erie St. Clair, South West,
Waterloo Wellington, Hamilton Niagara Haldimand
Brant, Central West, Mississauga Halton, Toronto
Central, Central, Central East, South East, Champlain,
North Simcoe Muskoka, North East, North West); and
clinical characteristics such as comorbidity, measured by
the Johns Hopkins Aggregated Diagnosis Groups (num-
ber of ADGs: 0, 1–3, 4–7, 8–10, 11+); stage at EAC
diagnosis (Stage 0-earliest stage of EAC, also called
high-grade dysplasia, where cancer cells are found only
in the epithelium, Stage I, Stage II, Stage III, Stage IV);
treatment for EAC (categorized exclusively as surgery,
chemotherapy or radiotherapy alone, surgery plus
chemotherapy, surgery plus radiotherapy, chemotherapy
plus radiotherapy, surgery plus chemotherapy plus radio-
therapy, and no treatment); year of EAC diagnosis
(2003–2011); and date of death. The OCR has used the
American Joint Committee on Cancer TNM staging [36]
from 2003 onwards.
Individual-level income quintile was not available;
therefore, area-level income quintile was used as a sur-
rogate. Area-level income quintile was quantified using
median neighbourhood household income, which was
determined through linking of postal codes to Canadian
census data and categorized into quintiles corresponding
to income status of neighbourhoods. The income quin-
tile 1 represents the lowest 20% of neighbourhoods and
income quintile 5 represents the most well-off 20% of
neighbourhoods.
Ontario has 14 health regions, called Local Health In-
tegration Networks (LHIN) [37] which we used as a fac-
tor to explain regional health care service and
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availability. The Johns Hopkins Adjusted Clinical Groups
case-mix system [38–41] was used for comorbidity
adjustment [42–44].
Estimates of the net cost of care for EAC patients:
Matching cases and controls
The net cost method matches cases and controls on
socio-demographic and clinical factors associated with re-
source use and calculates the difference in cost for cancer
patients and non-cancer control subjects [22, 24, 25].
Cases (cancer patients) were identified as all eligible indi-
viduals 18 years of age and older in the OCR with an
International Statistical Classification of Disease and Re-
lated Health Problems (ICD-9) site codes 150.0–150.9 and
ICD-10 codes (C15.3–C15.9), in combination with hist-
ology International Classification of Diseases for Oncol-
ogy, Third Edition (ICD-O-3) codes 8140–8575
corresponding to primary cancer (see Additional file 1:
Table S2) [45]. Individuals were excluded if the EAC diag-
nosis was recorded on or after the date of death or indi-
viduals whose EAC was not the primary site.
Potential controls were selected from a 5% random
sample of the reference Ontario population Registered
Persons Database, including all individuals 18 years of
age and older with no cancer diagnosis before or during
our analysis period. Control subjects who died before
the patient’s EAC diagnosis date were excluded.
Two sets of cases and controls were used to match 1:1
at two index dates (date of diagnosis and 12 months pre-
ceding the date of death) to estimate costs for the initial
and continuing care phases. For the latter index date,
cases who died were matched 1:1 to controls with simi-
lar conditional probability of a diagnosis of EAC given
the observed individual covariates [46, 47] who died on
the same date to estimate costs for the terminal phase.
This was derived by fitting a logistic model with EAC
status as the dependent variable and the index year (year
of EAC diagnosis), age group at index date, gender,
urban or rural residence, neighbourhood income quin-
tile, Ontario health region, and comorbidity [18, 35]. For
each case, the closest non-EAC control was selected that
matched the following criteria: age ± 5 years at the index
date; same gender; same index year; comorbidity
(ADGs), and a propensity score within a caliper width of
0.2 standard deviation [48].
Estimation of health care costs
Cost estimates for inpatient hospitalizations, same-day
surgery, and emergency department visits were obtained
by multiplying the resource intensity weight (measure of
resource utilization intensity) by the cost per weighted
case (unit cost) [32, 49–51]. Costs for services included
in Ontario Health Insurance Plan, Ontario Drug Benefit,
and Home Care were obtained by multiplying the
number of services by unit cost. Continuing care cost
was determined using Continuing Care Reporting Sys-
tem, which contains clinical and demographic informa-
tion on individuals receiving facility based continuing
care. Services include medical long-term care, rehabilita-
tion, geriatric assessment, respite care, palliative care,
and nursing home care. Patients are classified into 44
Resource Utilization Groups, and are assigned a Case
Mix Index that approximates their per day resource
usage. Case Mix Index is reviewed every quarter and can
be adjusted multiple times [32]. Continuing care cost
per weighted day was derived by dividing the total an-
nual cost by the total annual weighted day. The case cost
is the product of weighted days multiplied by the cost
per weighted day. The cost of long-term care was
obtained through the product of the year-specific length
of stay and the Ministry of Health cost per diem. All
costs were adjusted to 2016 Canadian dollars using the
Consumer Price Index for Health and Personal Care
[52]. Costs were undiscounted (i.e., exact costs billed).
Statistical analysis
Sociodemographic and clinical characteristics and health
care costs for the EAC cases and non-EAC control co-
horts were summarized by phase of care. We presented
categorical variables as frequencies and percentages, and
continuous variables as means ± standard deviations.
For each phase of care, we estimated mean (95% confi-
dence interval [CI]) net costs of care due to EAC (per 30
patient-days) using generalized estimating equations to
account for the matched study design. Estimates were
bootstrapped 1000 times to obtain CIs. Total net health
care costs and by phase of care were analyzed by stage
at EAC diagnosis and type of treatment received.
Generalized estimation equation model with a loga-
rithmic link and gamma distribution, which specifies the
conditional mean function directly, was used to examine
unadjusted and adjusted relationships between covari-
ates and total net health care costs per 30 patient-days
by phase of care among all EAC cases [53–55]. Potential
covariates included age at EAC diagnosis, gender, urban
or rural residence, birth country, income quintile,
Ontario health region, comorbid conditions (ADGs),
stage of disease at diagnosis, treatment for EAC, and
year of EAC diagnosis. Variables with a significance level
of P ≤ 0.2 in the univariate analyses were entered into
the multivariate generalized estimation regression ana-
lysis and were considered independently significant
when P ≤ 0.05 [56, 57]. Interactions were considered in
the context of regression analysis. The adjusted model
was constructed according to a stepwise backward selec-
tion methodology and only included those variables that
remained significant at the two-sided level of P ≤ 0.05
[57]. Finally, variables that were non-significant in the
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univariate test were added to see if they became signifi-
cant when adjusted for other factors [58]. Statistical ana-
lyses were conducted using SAS version 9.4 (SAS Institute
Inc., Cary, NC, USA).
Sensitivity analysis
A sensitivity analysis was performed where the initial
phase was defined as the first 6 months after diagnosis
of EAC, the terminal phase was defined as the final
6 months before death, and the continuing care phase
was defined as all months between the initial and ter-
minal phases of care.
Results
Characteristics of the study population
A flow chart of the study population is shown in Add-
itional file 2: Figure S1. Overall, 3035 EAC cases and
560,997 control subjects were identified during the study
period 2003–2011 (see Additional file 3: Table S3). Over
the period, the number of new EAC cases increased
from 285 in 2003 to 413 in 2011, and the proportion of
those with age group at diagnosis of 50–54, 55–59, 60–
64, 65–69, and 70–74 years increased from 5.8, 10.5, 8.3,
8.0, and 10.3% to 12.6, 17.1, 13.9, 18.3, and 12.5%, re-
spectively. Stage at EAC diagnosis was available from
2003 in the data; 126 (4.2%) people were diagnosed with
stage 0-I, while 420 (13.8%) were stage II, 455 (15.0%)
were stage III, 940 (31.0%) were stage IV, and 1094
(36.1%) were unknown stage. In addition, the proportion
of patients with known stages increased from 2003 to
2011; stage 0-I from 1.6 to 21.4%; stage II from 3.1 to
12.6%; stage III from 0.9 to 16.0%; and stage IV from 2.5
to 11.5%. Patients receiving treatment with radiotherapy
alone after EAC diagnosis increased from 5.2% in 2003
to 19.3% in 2011. In addition, those not receiving treat-
ment increased from 8.9 to 14.0%. In contrast, the pro-
portion of patients receiving surgery plus chemotherapy
decreased over time, from 13.6 to 5.1%. In our cohort,
2490 of EAC patients died during the mean 510 days or
median 288 days of follow-up and 18,536 of controls
died during the mean 2309 days or median 2373 days of
follow-up.
Table 1 describes the baseline characteristics of the
matched cases and controls by phase of care. Cases that
contributed person-time to the initial (259 days) and the
terminal phase (242 days) were closely matched to the
controls (initial phase: 360 days and terminal phase:
360 days); however, many cases that contributed
person-time to the continuing care phase could not be
matched with suitable controls (726 versus 1521 days).
Phase-specific health care costs and net costs of care
The average total health care costs per 30 patient-days
among EAC patients was relatively high in the initial
phase ($1139; 95% CI, $1079–$1199), declined during
the continuing care phase ($923; 95% CI, $852–$995),
and increased markedly in the terminal phase ($9004;
95% CI, $8545–$9462) (Table 2).
Estimates of the average total net costs of EAC care
per 30 patient-days were highest in the terminal phase
($8678, 96% of overall EAC net costs), followed by the
initial phase ($1016, 11%) and continuing care phase
($669, 7%) of overall EAC net costs (Table 3 and see
Additional file 4: Figure S2a-S2d). The net costs of
inpatient hospitalization (85–97% of the mean health
care costs of inpatient hospitalization in Table 2) and
outpatient visits (75–97% of the mean health care of out-
patient visits in Table 2) due to EAC accounted for the
highest cost categories across all three phases. We re-
ported bootstrap mean and 95% CIs derived from the
generalized estimating equations on Additional file 5:
Table S4. With large sample sizes, the bootstrap samples
results are similar to the original sample.
Total net costs of care by stage at diagnosis and
treatment for EAC
Stage IV at EAC diagnosis accounted the highest total
net costs per 30 patient-days and approximately 10% of
the total costs in the initial phase ($1010; 95% CI,
$887–$1134), 6% in the continuing care phase ($620;
95% CI, $461–$780), and 100% in the terminal phase
($10,000; 95% CI, $9106–$10,894). Stage 0-I at EAC
diagnosis accounted the lowest total costs. For stage 0-I,
16% of the total costs in the initial phase ($804; 95% CI,
$626–$982), 13% in the continuing care phase ($646;
95% CI, $481–$810), and 83% in the terminal phase
($4249; 95% CI, $1789–$6710) (Table 4 and see
Additional file 6: Figure S3a-S3d).
The mean net costs per 30 patient-days of patients re-
ceiving radiotherapy alone was highest in the initial phase
($1330; 95% CI, $1187–$1474) followed by surgery plus
chemotherapy plus radiotherapy ($1323; 95% CI,
$757–$1890), chemotherapy plus radiotherapy ($1129;
95% CI, ($909–$1350), chemotherapy alone ($1109; 95%
CI, $935–$1282), surgery plus chemotherapy ($1089; 95%
CI, $862–$1316), surgery plus radiotherapy ($1080; 95%
CI, $494–$1667), and surgery alone ($996; 95% CI,
$856–$1135). The mean costs of patients receiving sur-
gery plus chemotherapy ($878; 95% CI, $634–$1123) were
highest in the continuing care phase followed by surgery
alone ($868; 95% CI, $690–$1046) and chemotherapy plus
radiotherapy ($846; 95% CI, $650–$1042). The mean costs
of patients that received surgery plus radiotherapy were
highest in the terminal phase ($12,237; 95% CI,
$1541–$22,933) followed by those not receiving treatment
($10,238; 95% CI, $9512–$10,965) and those receiving
chemotherapy alone ($8168; 95% CI, $7091–$9245) (Table
4 and see Additional file 7: Figure S4a-S4d).
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Table 1 Matched cases (esophageal adenocarcinoma) and controls by phase of care, 2003–2011
Variable Initial Phase Continuing Care Phase Terminal Phase
Cases Controls Cases Controls Cases Controls
N (%) N (%) N (%) N (%) N (%) N (%)
N 1265 1265 632 632 3011 3011
Mean ± SD time spent (days) 259 ± 130 360 ± 34 726 ± 691 1521 ± 892 242 ± 130 360 ± 36
Age group at index date (years)
< 50 106 (8.4) 106 (8.4) 53 (8.4) 53 (8.4) 242 (8.0) 242 (8.0)
50–54 138 (10.9) 138 (10.9) 76 (12.0) 76 (12.0) 277 (9.2) 277 (9.2)
55–59 165 (13.0) 165 (13.0) 84 (13.3) 84 (13.3) 331 (11.0) 331 (11.0)
60–64 227 (17.9) 227 (17.9) 116 (18.4) 116 (18.4) 459 (15.2) 459 (15.2)
65–69 203 (16.1) 203 (16.1) 113 (17.9) 113 (17.9) 423 (14.1) 423 (14.1)
70–74 161 (12.7) 161 (12.7) 86 (13.6) 86 (13.6) 413 (13.7) 413 (13.7)
75–79 138 (10.9) 138 (10.9) 66 (10.4) 66 (10.4) 383 (12.7) 383 (12.7)
80–84 79 (6.3) 79 (6.3) 24 (3.8) 24 (3.8) 279 (9.3) 279 (9.3)
≥ 85 48 (3.8) 48 (3.8) 14 (2.2) 14 (2.2) 204 (6.8) 204 (6.8)
Gender
Female 198 (15.7) 198 (15.7) 86 (13.6) 86 (13.6) 499 (16.6) 499 (16.6)
Male 1067 (84.4) 1067 (84.4) 546 (86.4) 546 (86.4) 2512 (83.4) 2512 (83.4)
Residence
Urban 1033 (81.7) 1045 (82.6) 518 (82.0) 529 (83.7) 2464 (81.8) 2498 (83.0)
Rural 232 (18.3) 220 (17.4) 114 (18.0) 103 (16.3) 547 (18.2) 513 (17.0)
Income quintile
Q1 (lowest) 239 (18.9) 250 (19.8) 109 (17.3) 118 (18.7) 598 (19.9) 636 (21.1)
Q2 247 (19.5) 251 (19.8) 111 (17.6) 121 (19.2) 629 (20.9) 616 (20.5)
Q3 242 (19.1) 228 (18.0) 121 (19.2) 108 (17.1) 587 (19.5) 566 (18.8)
Q4 274 (21.7) 278 (22.0) 140 (22.2) 139 (22.0) 623 (20.7) 646 (21.5)
Q5 (highest) 263 (20.8) 258 (20.4) 151 (23.9) 146 (23.1) 574 (19.1) 547 (18.2)
Ontario health region
Erie St. Clair 65 (5.1) 65 (5.1) 35 (5.5) 37 (5.9) 153 (5.1) 149 (5.0)
South West 88 (7.0) 89 (7.0) 40 (6.3) 42 (6.7) 273 (9.1) 275 (9.1)
Waterloo Wellington 72 (5.7) 73 (5.8) 31 (4.9) 33 (5.2) 174 (5.8) 169 (5.6)
Hamilton Niagara Haldimand Brant 174 (13.8) 178 (14.1) 80 (12.7) 84 (13.3) 445 (14.8) 450 (15.0)
Central West 51 (4.0) 47 (3.7) 31 (4.9) 30 (4.8) 101 (3.4) 89 (3.0)
Mississauga 56 (4.4) 57 (4.5) 26 (4.1) 26 (4.1) 140 (4.7) 145 (4.8)
Toronto Central 78 (6.2) 82 (6.5) 38 (6.0) 40 (6.3) 199 (6.6) 207 (6.9)
Central 103 (8.1) 103 (8.1) 59 (9.3) 59 (9.3) 214 (7.1) 215 (7.1)
Central East 138 (10.9) 134 (10.6) 72 (11.4) 67 (10.6) 342 (11.4) 339 (11.3)
South East 94 (7.4) 89 (7.0) 48 (7.6) 44 (7.0) 210 (7.0) 203 (6.7)
Champlain 168 (13.3) 170 (13.4) 83 (13.1) 79 (12.5) 338 (11.2) 351 (11.7)
North Simcoe Muskoka 64 (5.1) 70 (5.5) 34 (5.4) 40 (6.3) 146 (4.9) 155 (5.2)
North East 79 (6.3) 78 (6.2) 38 (6.0) 35 (5.5) 193 (6.4) 194 (6.4)
North West 35 (2.8) 30 (2.4) 17 (2.7) 16 (2.5) 83 (2.8) 70 (2.3)
ADGs
0 4 (0.3) 4 (0.3) 3 (0.5) 3 (0.5) 15 (0.5) 15 (0.5)
1–3 49 (3.9) 49 (3.9) 21 (3.3) 21 (3.3) 117 (3.9) 117 (3.9)
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Predictors of total net costs of care in individuals
diagnosed with EAC
Univariate and multivariate predictors of total net costs of
care in individuals diagnosed with EAC are summarized
in Tables 5 and 6. Several patient characteristics were sig-
nificant predictors of total net costs of care per 30
patient-days. In the initial phase, predictors of higher costs
associated with EAC included all stages at EAC diagnosis
compared with stage 0-I (P < 0.001), all treatments for
EAC except surgery plus radiotherapy compared with no
treatment (P < 0.001), and year of EAC diagnosis from
2006 to 2011 compared with 2003 (P < 0.001) (Table 6).
The multivariate coefficients for stage indicate in the
initial phase, stage III compared to stage 0–1 cost $1.51
more per 30 patient-days controlling for other factors. Pa-
tients diagnosed with EAC on 2011 compared to 2003
cost $2.41 more per 30 patient-days, after controlling for
other factors. Patients who received surgery plus chemo-
therapy plus radiotherapy were associated with $2.57 in-
crease in cost per 30 patient-days compared to the no
treatment group controlling for all other factors.
In the continuing care phase, predictors of higher cost
associated with EAC included comorbidity measured by
the Johns Hopkins ADGs (from ADGs 1–3 to ADGs 11+
compared with no comorbidity, P < 0.001) and all treat-
ments for EAC except surgery plus radiotherapy and
Table 1 Matched cases (esophageal adenocarcinoma) and controls by phase of care, 2003–2011 (Continued)
Variable Initial Phase Continuing Care Phase Terminal Phase
Cases Controls Cases Controls Cases Controls
N (%) N (%) N (%) N (%) N (%) N (%)
4–7 235 (18.6) 235 (18.6) 118 (18.7) 118 (18.7) 549 (18.2) 549 (18.2)
8–10 341 (27.0) 341 (27.0) 155 (24.5) 154 (24.5) 803 (26.7) 803 (26.7)
11+ 636 (50.3) 636 (50.3) 335 (53.0) 335 (53.0) 1527 (50.7) 1527 (50.7)
Year of EAC diagnosis
2003 118 (9.3) 118 (9.3) 59 (9.3) 57 (9.3) 284 (9.4) 284 (9.4)
2004 126 (10.0) 126 (10.0) 74 (11.7) 74 (11.7) 288 (9.6) 288 (9.6)
2005 97 (7.7) 97 (7.7) 63 (10.0) 63 (10.0) 279 (9.3) 279 (9.3)
2006 139 (11.0) 139 (11.0) 71 (11.2) 71 (11.2) 320 (10.6) 320 (10.6)
2007 122 (9.6) 122 (9.6) 64 (10.1) 64 (10.1) 297 (9.9) 297 (9.9)
2008 139 (11.0) 139 (11.0) 81 (12.8) 81 (12.8) 349 (11.6) 349 (11.6)
2009 165 (13.0) 165 (13.0) 90 (14.2) 90 (14.2) 386 (12.8) 386 (12.8)
2010 181 (14.3) 181 (14.3) 85 (13.5) 85 (13.5) 397 (13.2) 397 (13.2)
2011 178 (14.1) 178 (14.1) 45 (7.1) 45 (7.1) 411 (13.7) 411 (13.7)
SD standard deviation, ADGs Aggregated Diagnosis Groups, EAC esophageal adenocarcinoma
Table 2 Mean health care costsa among EAC cases and non-EAC controls according to service category and phase of care, 2003–2011
Service category Initial Phase Continuing Care Phase Terminal Phase
Cases Controls Cases Controls Cases Controls
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
N 1285 2942 651 2870 3011 3011
Outpatient visits $170 ($164–$177) $16 ($15–$17) $157 ($150–$165) $40 ($38–$42) $1263 ($1199–$1327) $37 ($25–$49)
Emergency department
visits
$20 ($19–$22) $3 ($3–$4) $17 ($15–$18) $8 ($7–$8) $218 ($197–$240) $11 ($8–$13)
Same-day surgery $32 ($30–$34) $3 ($2–$3) $35 ($32–$37) $8 ($7–$8) $170 ($156–$185) $3 ($3–$3)
Inpatient hospitalization $491 ($452–$530) $36 ($30–$42) $404 ($357–$451) $60 ($55–$66) $5451 ($5084–$5818) $154 ($109–$198)
Medications $63 ($58–$68) $17 ($15–$18) $65 ($58–$73) $43 ($40–$46) $247 ($231–$264) $23 ($21–$25)
Home care $86 ($79–$93) $7 ($6–$8) $61 ($54–$68) $14 ($12–$16) $467 ($440–$494) $17 ($8–$27)
Continuing care $5 ($1–$8) $11 ($8–$14) $4 (−$1–$8) $22 ($17–$27) $20 ($10–$29) $23 ($14–$31)
Long-term care $9 ($5–$14) $20 ($16–$24) $8 ($2–$14) $32 ($25–$38) $43 ($31–$55) $42 ($32–$53)
Total cost $1139 ($1079–$1199) $122 ($110–$135) $923 ($852–$995) $254 ($232–$276) $9004 ($8545–$9462) $326 ($265–$387)
EAC esophageal adenocarcinoma, CI confidence intervals
aMean health care costs are expressed in 2016 Canadian dollars per 30 patient-days
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Table 3 Mean net costsa of care due to esophageal adenocarcinoma according to service category and phase of care, 2003–2011
Service category Overall Initial Phase Continuing Care Phase Terminal Phase
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
N 6022 4227 3521 6022
Outpatient visits $1279 ($1215–$1343) $155 ($148–$162) $117 ($109–$125) $1226 ($1161–$1291)
Emergency department visits $209 ($188–$231) $17 ($16–$18) $9 ($8–$11) $208 ($186–$230)
Same-day surgery $179 ($164–$193) $29 ($27–$31) $27 ($24–$30) $167 ($153–$182)
Inpatient hospitalization $5501 ($5135–$5867) $455 ($415–$494) $343 ($296–$390) $5297 ($4929–$5665)
Medications $207 ($190–$225) $46 ($41–$51) $22 ($14–$30) $224 ($208–$240)
Home care $479 ($450 –$509) $79 ($72–$86) $47 ($39–$55) $449 ($421–$478)
Continuing care -$32 (−$47– -$17) -$7 (−$11– -$2) -$18 (−$25– -$12) -$3 (−$15–$9)
Long-term care -$44 (−$64– -$24) -$11 (−$17– -$4) -$24 (−$33– -$15) $0 (−$15–$16)
Total net costs $9002 ($8547–$9456) $1016 ($955–$1078) $669 ($594–$743) $8678 ($8217–$9139)
Net costs of care due to esophageal adenocarcinoma were generated using generalized estimating equations
EAC esophageal adenocarcinoma, CI confidence intervals
aMean health care costs are expressed in 2016 Canadian dollars per 30 patient-days
Table 4 Overall and phase of care net cost of health care resources by stage at diagnosis and treatment type for the esophageal
adenocarcinoma cohort, 2003–2011
Cost category Overall Initial Phase Continuing Care Phase Terminal Phase
Meana (95% CI) N (Cases) Meana (95% CI) N (Cases) Meana (95% CI) N (Cases) Meana (95% CI)
Stage at EAC diagnosis
Stage 0-I $5094
($2659–$7529)
102 $804
($626–$982)
64 $646
($481–$810)
126 $4249
($1789–$6710)
Stage II $6192
($5368–$7015)
282 $999
($887–$1111)
161 $696
($600–$791)
416 $5426
($4574–$6277)
Stage III $7413
($6679–$8147)
273 $1254
($1142–$1366)
136 $708
($565–$851)
451 $6652
($5879–$7425)
Stage IV $9978
($9093–$10,864)
222 $1010
($887–$1134)
74 $620
($461–$780)
930 $10,000
($9106–$10,894)
Type of EAC treatment
Surgery alone $7785
($6667–$8903)
361 $996
($856–$1135)
215 $868
($690–$1046)
533 $6937
($5802–$8071)
Chemotherapy alone $8607
($7565–$9650)
161 $1109 ($935–$1282) 86 $590
($466–$715)
338 $8168
($7091–$9245)
Radiotherapy alone $7998
($7095–$8901)
228 $1330
($1187–$1474)
118 $630
($518–$742)
405 $7285
($6344–$8225)
Surgery + chemotherapy $5801
($4751–$6850)
81 $1089
($862–$1316)
52 $878
($634–$1123)
118 $4832
($3710–$5954)
Surgery + radiotherapy $12,417
($2067–$22,767)
– $1080
($494–$1667)
– $170
(−$200–$539)
6 $12,237
($1541–$22,933)
Chemotherapy + radiotherapy $7671
($6023–$9320)
68 $1129
($909–$1350)
40 $846
($650–$1042)
109 $6849
($5107–$8590)
Surgery + chemotherapy
+ radiotherapy
$4743
($1755–$7731)
7 $1323
($757–$1890)
– $236
($111–$362)
7 $3519
($684–$6354)
No treatment $10,152
($9431–$10,873)
377 $765
($688–842)
136 $318
($243–$393)
1495 $10,238
($9512–$10,965)
aMean health care costs are expressed in 2016 Canadian dollars per 30 patient-days. ‘–’, counts less than six are suppressed
EAC esophageal adenocarcinoma, CI confidence intervals
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Table 5 Predictors of total net costs of care in individuals with a diagnosis of esophageal adenocarcinoma according to phase of care, 2003–2011: Univariate generalized
estimation equations
Variable Initial Phase Continuing Care Phase Terminal Phase
Estimate 95% CI P-value Estimate 95% CI P-value Estimate 95% CI P-value
N = 4178 N = 3472 N = 5972
Age group at index date (years)*
< 50 Reference Reference Reference
50–54 0.112 − 0.121–0.343 0.343 0.303 0.087–0.518 0.006 −0.038 − 0.272–0.194 0.749
55–59 − 0.011 − 0.236–0.211 0.921 0.104 − 0.106–0.311 0.328 − 0.106 − 0.331–0.117 0.355
60–64 0.022 − 0.191–0.230 0.838 0.340 0.141–0.534 0.001 0.008 − 0.205–0.216 0.942
65–69 0.162 − 0.053–0.374 0.135 0.549 0.349–0.746 < 0.001 0.006 −0.210–0.217 0.960
70–74 0.156 −0.063–0.372 0.158 0.751 0.548–0.951 < 0.001 0.246 0.030–0.458 0.024
75–79 − 0.041 − 0.264–0.179 0.716 0.786 0.578–0.990 < 0.001 0.220 0.001–0.435 0.047
80–84 0.184 − 0.059–0.426 0.137 0.854 0.624–1.085 < 0.001 0.238 0.004–0.470 0.045
≥ 85 0.273 0.003–0.549 0.049 0.992 0.730–1.260 < 0.001 0.328 0.076–0.581 0.011
Gender
Male Reference Reference Reference
Female 0.006 −0.125–0.141 0.928 0.084 − 0.041–0.213 0.193 0.041 − 0.087–0.172 0.539
Residence
Urban Reference Reference Reference
Rural −0.006 − 0.133–0.124 0.924 − 0.073 − 0.194–0.052 0.246 0.001 − 0.124–0.129 0.987
Birth country
Outside of Canada Reference Reference Reference
Canada 0.006 − 0.130–0.139 0.932 0.067 −0.173–0.298 0.574 0.020 −0.073–0.112 0.668
Income quintile†
Q1 (lowest) − 0.040 − 0.196–0.116 0.619 0.017 − 0.131–0.164 0.822 0.141 − 0.013–0.295 0.072
Q2 −0.077 − 0.234–0.079 0.331 − 0.023 − 0.172–0.125 0.758 0.213 0.059–0.366 0.007
Q3 −0.091 − 0.250–0.068 0.260 − 0.067 − 0.217–0.084 0.383 0.247 0.090–0.404 0.002
Q4 0.043 −0.111–0.196 0.587 0.151 0.005–0.296 0.042 0.117 −0.037–0.27 0.135
Q5 (highest) Reference Reference Reference
Ontario health region**
Central Reference Reference Reference
Erie St. Clair −0.073 −0.353–0.212 0.610 0.061 −0.200–0.327 0.649 0.052 −0.227–0.335 0.716
South West −0.071 − 0.316–0.174 0.571 − 0.326 − 0.557– − 0.097 0.005 0.173 − 0.069–0.412 0.159
Waterloo Wellington 0.085 − 0.186–0.360 0.539 −0.094 − 0.351–0.166 0.475 0.214 − 0.055–0.486 0.121
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Table 5 Predictors of total net costs of care in individuals with a diagnosis of esophageal adenocarcinoma according to phase of care, 2003–2011: Univariate generalized
estimation equations (Continued)
Variable Initial Phase Continuing Care Phase Terminal Phase
Estimate 95% CI P-value Estimate 95% CI P-value Estimate 95% CI P-value
N = 4178 N = 3472 N = 5972
Hamilton Niagara Haldimand Brant 0.048 −0.174–0.265 0.666 0.011 −0.198–0.216 0.917 0.062 −0.160–0.279 0.579
Central West 0.383 0.068–0.712 0.020 0.326 0.031–0.633 0.033 0.144 −0.175–0.476 0.386
Mississauga 0.018 −0.266–0.309 0.901 −0.090 − 0.358–0.184 0.513 0.235 − 0.048–0.523 0.106
Toronto Central 0.046 −0.214–0.308 0.729 0.328 0.082–0.576 0.009 0.291 0.032–0.551 0.028
Central East −0.035 − 0.267–0.194 0.767 −0.060 − 0.278–0.155 0.586 0.053 − 0.179–0.281 0.651
South East 0.051 −0.206–0.309 0.696 0.049 −0.193–0.292 0.692 −0.085 − 0.342–0.172 0.515
Champlain 0.047 −0.182–0.272 0.686 0.043 −0.173–0.256 0.691 0.032 −0.199–0.260 0.782
North Simcoe Muskoka −0.025 − 0.304–0.259 0.861 − 0.014 − 0.276–0.254 0.920 0.026 − 0.252–0.309 0.855
North East − 0.046 − 0.308–0.218 0.732 − 0.090 − 0.337–0.158 0.474 0.245 − 0.017–0.507 0.067
North West 0.010 − 0.338–0.379 0.957 − 0.026 − 0.359–0.329 0.884 0.164 − 0.178–0.525 0.359
ADGs‡
0 Reference Reference Reference
1–3 0.201 −1.302–1.236 0.747 0.642 −0.719–1.609 0.263 −0.341 −1.393–0.470 0.463
4–7 0.083 −1.407–1.087 0.893 0.801 −0.547–1.738 0.155 −0.564 − 1.595–0.212 0.212
8–10 0.211 − 1.277–1.213 0.729 1.045 − 0.301–1.980 0.063 − 0.507 − 1.537–0.265 0.259
11+ 0.334 − 1.153–1.334 0.584 1.504 0.159–2.436 0.008 −0.472 −1.501–0.297 0.293
Stage at EAC diagnosis§
Stage 0-I Reference Reference Reference
Stage II 0.191 0.006–0.371 0.040 0.054 − 0.164–0.266 0.621 0.229 0.014–0.435 0.033
Stage III 0.396 0.210–0.577 < 0.001 0.067 − 0.157–0.284 0.551 0.422 0.209–0.627 < 0.001
Stage IV 0.201 0.010–0.388 0.037 −0.028 − 0.277–0.219 0.823 0.814 0.613–1.006 < 0.001
EAC treatment¶
No treatment Reference Reference Reference
Surgery alone 0.231 0.106–0.356 < 0.001 0.673 0.512–0.832 < 0.001 −0.375 − 0.485– − 0.263 < 0.001
Chemotherapy alone 0.327 0.170–0.489 < 0.001 0.389 0.189–0.592 < 0.001 − 0.218 − 0.349– − 0.084 0.001
Radiotherapy alone 0.493 0.352–0.636 < 0.001 0.435 0.251–0.619 < 0.001 −0.328 − 0.450– − 0.203 < 0.001
Surgery + chemotherapy 0.312 0.108–0.524 0.003 0.682 0.447–0.925 < 0.001 − 0.717 − 0.921– − 0.500 < 0.001
Surgery + radiotherapy 0.304 − 0.700–1.799 0.620 − 0.300 −1.193–0.953 0.572 0.173 − 0.610–1.228 0.705
Chemotherapy + radiotherapy 0.344 0.126–0.574 0.003 0.653 0.396–0.923 < 0.001 −0.387 − 0.598– − 0.162 0.001
Surgery + chemotherapy + radiotherapy 0.488 − 0.098–1.210 0.139 − 0.154 −1.047–1.098 0.771 −1.011 − 1.743– − 0.046 0.017
T
h
e
in
e
t
a
l.
B
M
C
C
a
n
c
e
r
 (2
0
1
8
) 1
8
:6
9
4
 
P
a
g
e
1
0
o
f
1
9
Table 5 Predictors of total net costs of care in individuals with a diagnosis of esophageal adenocarcinoma according to phase of care, 2003–2011: Univariate generalized
estimation equations (Continued)
Variable Initial Phase Continuing Care Phase Terminal Phase
Estimate 95% CI P-value Estimate 95% CI P-value Estimate 95% CI P-value
N = 4178 N = 3472 N = 5972
Year of EAC diagnosis€
2003 Reference Reference Reference
2004 0.015 −0.208–0.238 0.896 0.010 −0.193–0.213 0.922 −0.131 − 0.352–0.090 0.245
2005 −0.056 − 0.285–0.174 0.633 − 0.158 − 0.365–0.049 0.134 0.064 − 0.159–0.287 0.573
2006 0.401 0.183–0.619 < 0.001 0.073 − 0.129–0.273 0.478 0.033 − 0.183–0.248 0.763
2007 0.292 0.069–0.514 0.010 −0.053 − 0.257–0.150 0.607 0.175 − 0.044–0.394 0.117
2008 0.367 0.151–0.581 0.001 −0.181 − 0.377–0.014 0.069 0.351 0.139–0.561 0.001
2009 0.527 0.316–0.735 < 0.001 −0.274 − 0.467– − 0.084 0.005 0.327 0.119–0.532 0.002
2010 0.462 0.253–0.668 < 0.001 −0.729 − 0.922– −0.539 < 0.001 0.310 0.103–0.514 0.003
2011 0.541 0.333–0.746 < 0.001 −1.723 − 1.916– − 1.531 < 0.001 0.222 0.016–0.425 0.033
Initial Phase, overall P values (unadjusted): *age group at index date: P = 0.084; †income quintile: P = 0.405; **Ontario health region: P = 0.541; ‡ADGs: P < 0.005; §stage at EAC diagnosis: P < 0.001; ¶treatment for EAC: P <
0.001; €year of EAC diagnosis: P < 0.001
Continuing Care Phase, overall P values (unadjusted): *age group at index date: P < 0.001; †income quintile: P = 0.038; **Ontario health region: P < 0.001; ‡ADGs: P < 0.001; §stage at EAC diagnosis: P = 0.794; ¶treatment
for EAC: P < 0.001; €year of EAC diagnosis: P < 0.001
Terminal Phase, overall P values (unadjusted): *age group at index date: P < 0.001; †income quintile: P = 0.022; **Ontario health region: P = 0.176; ‡ADGs: P = 0.304; §stage at EAC diagnosis: P < 0.001; ¶treatment for EAC:
P < 0.001; €year of EAC diagnosis: P < 0.001
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Table 6 Predictors of total net costs of care in individuals with a diagnosis of esophageal adenocarcinoma according to phase of care, 2003–2011: Multivariate generalized
estimation equations with a log link function and gamma distribution
Variable Initial Phase Continuing Care Phase Terminal Phase
Estimate 95% CI P-value Estimate 95% CI P-value Estimate 95% CI P-value
Intercept 6.012 5.588–6.461 < 0.001 4.402 3.653–5.338 < 0.001 7.718 7.176–8.288 < 0.001
Age group at index date (years)*
< 50 Reference Reference
50–54 − 0.021 − 0.243–0.200 0.853 −0.024 − 0.239–0.189 0.823
55–59 − 0.102 − 0.321–0.114 0.355 −0.175 − 0.385–0.033 0.099
60–64 − 0.111 − 0.317–0.092 0.289 −0.004 − 0.203–0.193 0.971
65–69 0.085 − 0.127–0.295 0.428 −0.100 − 0.302–0.100 0.331
70–74 0.064 −0.159–0.286 0.572 0.276 0.068–0.483 0.009
75–79 −0.184 − 0.409–0.041 0.109 0.125 −0.086–0.334 0.242
80–84 − 0.049 − 0.315–0.221 0.718 0.040 −0.190–0.271 0.732
≥ 85 −0.377 − 0.703– − 0.036 0.027 0.181 − 0.113–0.484 0.235
Residence
Urban Reference
Rural −0.159 −0.293– − 0.022 0.022
Income quintile†
Q1 (lowest) 0.156 −0.007–0.320 0.061
Q2 −0.074 −0.239–0.091 0.378
Q3 −0.069 − 0.232–0.094 0.406
Q4 −0.112 − 0.269–0.045 0.162
Q5 (highest) Reference
Ontario health region**
Central Reference
Erie St. Clair 0.107 −0.180–0.401 0.468 0.137 − 0.148–0.425 0.348
South West −0.181 − 0.460–0.102 0.205 0.151 − 0.098–0.397 0.233
Waterloo Wellington −0.029 − 0.326–0.277 0.851 0.356 0.089–0.623 0.009
Hamilton Niagara Haldimand Brant 0.026 −0.212–0.262 0.829 0.101 − 0.122–0.317 0.369
Central West 0.169 −0.137–0.485 0.284 −0.125 − 0.471–0.238 0.488
Mississauga 0.103 −0.216–0.433 0.534 0.213 −0.118–0.558 0.216
Toronto Central 0.122 −0.160–0.409 0.401 0.197 −0.073–0.469 0.154
Central East 0.076 −0.165–0.315 0.537 −0.080 − 0.320–0.158 0.513
South East −0.227 − 0.491–0.039 0.093 − 0.067 − 0.319–0.182 0.598
Champlain 0.200 −0.035–0.432 0.093 0.117 −0.117–0.346 0.322
North Simcoe Muskoka −0.047 − 0.333–0.245 0.747 0.030 − 0.250–0.314 0.833
North East −0.103 − 0.387–0.188 0.483 0.396 0.124–0.670 0.004
North West −0.537 − 0.899– − 0.152 0.005 0.405 0.086–0.734 0.014
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Table 6 Predictors of total net costs of care in individuals with a diagnosis of esophageal adenocarcinoma according to phase of care, 2003–2011: Multivariate generalized
estimation equations with a log link function and gamma distribution (Continued)
Variable Initial Phase Continuing Care Phase Terminal Phase
Estimate 95% CI P-value Estimate 95% CI P-value Estimate 95% CI P-value
ADGs‡
0 Reference
1–3 1.619 0.659–2.408 < 0.001
4–7 1.636 0.707–2.373 < 0.001
8–10 1.712 0.788–2.442 < 0.001
11+ 1.897 0.975–2.623 < 0.001
Stage at EAC diagnosis§
Stage 0-I Reference Reference
Stage II 0.220 0.043–0.392 0.014 0.085 −1.167–1.938 0.911
Stage III 0.414 0.236–0.587 < 0.001 0.900 0.461–1.315 < 0.001
Stage IV 0.325 0.135–0.511 0.001 1.697 0.640–3.143 0.006
EAC treatment¶
No treatment Reference Reference Reference
Surgery alone 0.237 0.087–0.386 0.002 0.658 0.500–0.815 < 0.001 −4.123 −6.577– −0.977 0.001
Chemotherapy alone 0.190 0.012–0.371 0.038 0.420 0.223–0.620 < 0.001 −1.309 −3.154–0.547 0.150
Radiotherapy alone 0.407 0.250–0.565 < 0.001 0.513 0.334–0.693 < 0.001 −0.841 −2.750–1.280 0.387
Surgery + chemotherapy 0.423 0.185–0.671 0.001 0.590 0.362–0.824 < 0.001 −1.290 −2.019– −0.464 0.001
Surgery + radiotherapy 0.733 −0.491–2.695 0.338 −0.510 −1.375–0.653 0.312 − 0.038 − 1.564–2.854 0.970
Chemotherapy + radiotherapy 0.449 0.209–0.699 < 0.001 0.617 0.368–0.876 < 0.001 −1.292 −3.592–1.863 0.310
Surgery + chemotherapy + radiotherapy 0.942 0.243–1.810 0.017 −0.104 − 0.974–1.061 0.837 − 0.808 −2.210–1.287 0.344
Year of EAC diagnosis€
2003 Reference Reference Reference
2004 0.184 − 0.212–0.555 0.346 0.012 − 0.236–0.258 0.924 −0.085 − 0.459–0.267 0.647
2005 0.357 −0.044–0.734 0.071 0.095 −0.154–0.343 0.454 0.420 0.050–0.768 0.022
2006 0.615 0.229–0.973 0.001 0.355 0.108–0.600 0.005 0.342 − 0.020–0.679 0.054
2007 0.379 −0.010–0.742 0.047 0.276 0.026–0.525 0.030 0.473 0.108–0.814 0.009
2008 0.653 0.271–1.007 0.001 0.311 0.071–0.547 0.010 0.561 0.202–0.894 0.001
2009 0.815 0.433–1.168 < 0.001 0.224 −0.015–0.460 0.064 0.660 0.303–0.991 < 0.001
2010 0.675 0.294–1.026 < 0.001 −0.099 − 0.339–0.139 0.417 0.537 0.180–0.868 0.002
2011 0.878 0.495–1.231 < 0.001 −0.458 − 0.735– − 0.178 0.001 0.531 0.169–0.869 0.003
Income quintile-Comorbidity interaction††
Q1 (lowest)*ADGs −0.036 − 0.184–0.112 0.629
Q2*ADGs −0.096 − 0.165– − 0.027 0.006
Q3*ADGs 0.017 −0.041–0.077 0.563
Q4*ADGs −0.063 −0.111– − 0.016 0.009
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Table 6 Predictors of total net costs of care in individuals with a diagnosis of esophageal adenocarcinoma according to phase of care, 2003–2011: Multivariate generalized
estimation equations with a log link function and gamma distribution (Continued)
Variable Initial Phase Continuing Care Phase Terminal Phase
Estimate 95% CI P-value Estimate 95% CI P-value Estimate 95% CI P-value
Comorbidity-EAC stage interaction‡‡
ADGs 1–3*EAC stage II 1.132 −0.820–2.588 0.173
ADGs 1–3*EAC stage III −0.446 −1.181–0.319 0.242
ADGs 1–3*EAC stage IV −0.733 −2.219–0.399 0.256
ADGs 4–7*EAC stage II 0.274 − 1.578–1.519 0.715
ADGs 4–7*EAC stage III −0.090 −0.482–0.304 0.652
ADGs 4–7*EAC stage IV −0.479 −1.903–0.530 0.424
ADGs 8–10*EAC stage II 0.274 −1.569–1.500 0.712
ADGs 8–10*EAC stage III −0.269 −0.610–0.072 0.122
ADGs 8–10*EAC stage IV −0.821 −2.239–0.176 0.168
ADGs 11 + *EAC stage II 0.345 −1.490–1.554 0.639
ADGs 11 + *EAC stage IV −0.535 −1.950–0.456 0.367
Comorbidity-EAC treatment interaction‡‡‡
ADGs 1–3*Surgery alone 4.145 0.983–6.626 0.001
ADGs 1–3*Chemotherapy alone 0.885 −1.062–2.881 0.364
ADGs 1–3*Radiotherapy alone 1.126 −1.021–3.076 0.256
ADGs 1–3*Surgery + chemotherapy −1.279 −3.018–1.679 0.238
ADGs 1–3*Chemotherapy + radiotherapy 1.926 −1.213–4.247 0.128
ADGs 4–7*Surgery alone 3.650 0.514–6.087 0.004
ADGs 4–7*Chemotherapy alone 1.304 −0.444–3.054 0.126
ADGs 4–7*Radiotherapy alone 1.135 − 0.936–2.983 0.227
ADGs 4–7*Surgery + chemotherapy −0.003 − 0.684–0.729 0.993
ADGs 4–7*Surgery + radiotherapy −1.133 −4.416–2.149 0.433
ADGs 4–7*Chemotherapy + radiotherapy 1.982 −1.091–4.148 0.100
ADGs 4–7*Surgery + chemotherapy + radiotherapy 0.274 −1.907–2.458 0.792
ADGs 8–10*Surgery alone 3.884 0.754–6.313 0.002
ADGs 8–10*Chemotherapy alone 1.419 −0.318–3.156 0.093
ADGs 8–10*Radiotherapy alone 0.784 −1.282–2.625 0.402
ADGs 8–10*Surgery + chemotherapy 0.319 −0.281–0.943 0.304
ADGs 8–10*Surgery + radiotherapy 0.135 −3.125–3.394 0.925
ADGs 8–10*Chemotherapy + radiotherapy 2.654 −0.410–4.800 0.027
ADGs 11 + *Surgery alone 4.185 1.060–6.604 0.001
ADGs 11 + *Chemotherapy alone 1.225 −0.499–2.950 0.143
ADGs 11 + *Radiotherapy alone 0.986 −1.076–2.823 0.291
ADGs 11 + *Chemotherapy + radiotherapy 2.253 −0.808–4.395 0.059
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Table 6 Predictors of total net costs of care in individuals with a diagnosis of esophageal adenocarcinoma according to phase of care, 2003–2011: Multivariate generalized
estimation equations with a log link function and gamma distribution (Continued)
Variable Initial Phase Continuing Care Phase Terminal Phase
Estimate 95% CI P-value Estimate 95% CI P-value Estimate 95% CI P-value
EAC stage-EAC treatment interaction§§
EAC stage II*Surgery alone 0.107 −0.446–0.668 0.706
EAC stage II*Chemotherapy alone 0.031 −0.819–0.814 0.940
EAC stage II*Radiotherapy alone −0.161 −0.814–0.476 0.622
EAC stage II*Surgery + chemotherapy 0.667 −0.294–1.576 0.158
EAC stage II*Chemotherapy + radiotherapy −1.105 −2.191– −0.146 0.031
EAC stage III*Surgery alone −0.182 −0.725–0.368 0.513
EAC stage III*Chemotherapy alone −0.310 −1.158–0.470 0.452
EAC stage III*Radiotherapy alone −0.215 − 0.861–0.415 0.506
EAC stage III*Surgery + chemotherapy 1.146 0.194–2.038 0.014
EAC stage III*Chemotherapy + radiotherapy −0.804 −1.894–0.158 0.119
EAC stage III*Surgery + chemotherapy + radiotherapy 0.397 −1.813–2.610 0.707
EAC stage IV*Surgery alone −0.091 −0.664–0.497 0.759
EAC stage IV*Chemotherapy alone −0.115 −0.921–0.612 0.767
EAC stage IV*Radiotherapy alone −0.135 − 0.757–0.471 0.666
EAC stage IV*Surgery + chemotherapy 1.315 0.326–2.272 0.008
EAC stage IV*Chemotherapy + radiotherapy −1.162 −2.233– −0.224 0.021
CI confidence interval, ADGs Aggregated Diagnosis Groups, EAC esophageal adenocarcinoma
Initial Phase: final multivariable analysis adjusted for age group at index date, residence, income quintile, stage at EAC diagnosis. Treatment for EAC, and year of EAC diagnosis (index date). Residence and income quintile
variables that were non-significant in the univariate analysis were added in the final model and became significant. Overall P values (adjusted): *age group at index date: P = 0.045; †income quintile: P = 0.009; §stage at EAC
diagnosis: P < 0.001; ¶treatment for EAC: P < 0.001; €year of EAC diagnosis: P < 0.001
Continuing Care Phase: final multivariable analysis adjusted for Ontario health region, comorbidity, measured by the Johns Hopkins ADGs, treatment for EAC, and year of EAC diagnosis (index date). Overall P values
(adjusted): **Ontario health region: P = 0.008; ‡comorbidity: P < 0.001; ¶treatment for EAC: P < 0.001; €year of EAC diagnosis: P < 0.001
Terminal Phase: final multivariable analysis adjusted for age group at index date, Ontario health region, stage at EAC diagnosis, treatment for EAC, year of EAC diagnosis (index date), income quintile and comorbidity
interaction, comorbidity and stage at EAC diagnosis interaction, comorbidity and EAC treatment interaction, and stage at EAC diagnosis and treatment for EAC interaction. Overall P values (adjusted): *age group at index
date: P < 0.001; **Ontario health region: P < 0.001; §stage at EAC diagnosis: P < 0.001; ¶treatment for EAC: P = 0.025; €year of EAC diagnosis: P < 0.001; ††Income quintile-Comorbidity interaction: P = 0.006; ‡‡Comorbidity-EAC
stage interaction: P = 0.009; ‡‡‡Comorbidity- EAC treatment interaction: P = 0.010; §§EAC stage-EAC treatment interaction: P = 0.002
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surgery plus chemotherapy plus radiotherapy (P < 0.001),
and year of EAC diagnosis from 2006 to 2008 (P < 0.05).
In the terminal phase, predictors of higher cost associ-
ated with EAC included 70–74 years of age at index date
(P = 0.009), Ontario health region (Waterloo Wellington,
P = 0.009; North East, P = 0.004; and North West, P =
0.014), stage III (P < 0.001) and stage IV (P = 0.006) at EAC
diagnosis, year of EAC diagnosis from 2005 to 2011 (ex-
cept 2006; P < 0.001), comorbidity (ADGs 1–3, 4–7, 8–10
and 11+) and surgery alone interaction (P = 0.001, P =
0.004, P = 0.002 and P = 0.001, respectively), comorbidity
(ADGs 8–10) and chemotherapy plus radiotherapy inter-
action (P = 0.027) and EAC stage-EAC surgery plus
chemotherapy interactions (stage III, P = 0.014) and stage
IV (P = 0.008) (Table 6). In the terminal phase, patients in
stage IV were associated with $5.46 increase in cost per 30
patient-days compared to those in stage 0–1 controlling
for other factors.
Sensitivity analysis
In the sensitivity analysis assigning 6 months after the
diagnosis to the initial phase and 6 months preceding
death to the terminal phase, there was a significant
increase (85%) in the total net costs of care in the con-
tinuing care phase and a modest increase (42%) in the
initial phase compared with the total net costs of care in
the primary analysis (Additional file 8: Table S5). The
mean net costs of surgery plus radiotherapy (108%) and
all treatments significantly increased in the initial phase
(23–108%) and continuing care phase (63–639%), respect-
ively compared with the primary analysis (Additional file
8: Table S6). Predictors of total net costs of care associated
with EAC were similar to the primary analysis in the ter-
minal phase (Additional file 8: Table S7).
Discussion
This population-based retrospective cohort study ex-
amined phase-specific net costs of care per 30
patient-days attributable to EAC from a public payer
perspective, total net costs of care by stage and treat-
ment for EAC, and predictors of total net costs of
care in individuals diagnosed with EAC by phase of
care. The aggregated total net health care costs of
EAC care were highest in the terminal phase, next
highest in the initial phase, and the lowest cost was
in the continuing care phase. Inpatient hospitaliza-
tions accounted for the largest share of costs in all
phases, followed by outpatient visits and home care.
Overall, stage IV at diagnosis and surgery plus radio-
therapy for EAC accounted for the highest cost, in
particular in the terminal phase. The factors that were
associated with higher net costs of care included
treatment for EAC, especially chemotherapy plus
radiotherapy, surgery plus chemotherapy, radiotherapy
alone, surgery alone, and chemotherapy alone in the
initial and continuing care phases; intermediate or ad-
vanced stage and the latest year of EAC diagnosis in
the initial and terminal phases; comorbidity in the
continuing care phase; and older age at diagnosis
(70–74 years) and Ontario health region (Waterloo
Wellington, North East, North West) in the terminal
phase. Associations like older age and lower income
quintile may reflect medical factors such as comor-
bidity, or social factors like lesser social support that
could lead to higher use of medical services. Finally,
lower costs were associated with individuals diagnosed
with EAC included 85 years of age and older at index
date and rural residence in the initial phase.
Phase-specific costs are useful for estimating
incidence-based and long-term care costs, defined as
cumulative costs from the date of diagnosis to death
[22]. In addition, phase-specific cost estimates constitute
an important input for economic evaluation of preven-
tion, screening, and treatment interventions [21, 22, 25].
Our phase-specific costing approach provided in-depth
cost analysis to the specific net phase of care costs for
EAC, compared to previous studies which only looked at
overall costs. Recent and past studies analyzing hospital
costs after complex esophageal surgical procedures indi-
cate that postoperative complications are associated with
increased resource utilization and costs [59, 60]. Such
complications were captured in the phased costing ap-
proach we used. According to a large randomized trial,
preoperative chemoradiotherapy is safe and leads to a
significant increase in overall survival among patients
with localized adenocarcinoma or squamous-cell carcin-
oma of the esophagus compared with those treated with
surgery alone [61]. Esophageal cancer is often in an ad-
vanced stage when it is diagnosed, however. At later
stages, esophageal cancer can be treated but not cured.
The selection of prevention and treatment activities at
different stages of disease can have significant impact on
resource utilization [21, 62].
The strengths of our study include comprehensive cost
estimation and rigorous propensity score matching be-
tween cases and controls, which was based on sociode-
mographic and comorbidity characteristics, providing
unbiased estimates of the net costs of care. Our study
results can inform publically funded health care systems
on the cost of treatments for patients, considering stage
and other sociodemographic and clinical patient charac-
teristics. It can also aid detailed future planning of health
care costs.
Our study has some limitations. Our cost estimates
did not reflect the overall economic burden of EAC to
the society. Because Ontario only provides comprehen-
sive coverage for the elderly and those on social assist-
ance, prescription medication costs were not included
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for patients < 65 years. However, 1722 (56.7%) of our
patients are over age 65 years, and prescription drug
costs only accounted for 10% of total costs for patients
in this age group. Therefore, it is unlikely that the costs
for prescription drug cost for patients under age 65
would significantly change our results. Additionally,
since we matched patients on age, the missing prescrip-
tion drug costs, which contributes towards the total
costs, is also matched for cases and controls (patients
who are matched and under 65 will not have this cost
accounted for in the total compared to matched patients
over the age of 65 which will have the cost included in
total for cases and controls). No difference in results
would be expected as the missing prescription is homo-
genously distributed between cases and controls.
Although multiple imputation would provide a solution
for missing data, in our case there is no readily available
data for which to impute the cost of prescription drugs
for patients under the age of 65. Prescription drug costs
for patients over the age of 65 would not be valid to im-
pute for patients under the age of 65. We therefore did
not impute the value of prescription costs for patients
with missing prescription drug costs. Moreover, a limita-
tion of our study was that only overall cost was provided
by type for patients. Individual health care costs with
dates were not provided. Therefore, we were not able to
investigate cost thresholds to determine cost phase
boundaries and instead had to rely on previous research
to determine cost phases. Furthermore, we estimated
direct health care costs only and did not include patient
out-of-pocket costs or loss of productivity, which are im-
portant elements of the cost of illness for society and in-
dividuals. Finally, we could not assess the effect of
screening prior to Barrett’s esophagus or cancer diagno-
sis on costs. EAC patients with a prior Barrett’s esopha-
gus diagnosis are commonly diagnosed with earlier stage
disease and have improved survival compared with EAC
patients with no prior Barrett’s esophagus diagnosis
[63, 64].
Conclusions
Our phase-specific longitudinal net costing approach for
patients diagnosed with EAC until death identified three
distinct cost phases, and found that costs were highest
in the terminal phase, where inpatient hospitalization
cost was the greatest contributor to total costs than in
other phases. Furthermore, our findings suggest that the
economic burden of EAC is significant and is expected
to continue to increase due to the growth and aging of
the population, the increase in the incidence of EAC, co-
morbidity, disease progression, and the potentially ex-
pensive treatments of the future. Further research is
needed on methods to incorporate these phase-based
costs into cost-effectiveness analyses for EAC treatment.
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